Swiss National Bank Takes $42.43 Million Position in Revvity, Inc. (NYSE:RVTY)

Swiss National Bank bought a new stake in Revvity, Inc. (NYSE:RVTY - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 388,200 shares of the company's stock, valued at approximately $42,434,000. Swiss National Bank owned approximately 0.31% of Revvity as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also made changes to their positions in RVTY. Byrne Asset Management LLC bought a new position in Revvity during the 4th quarter worth approximately $1,112,000. State of Michigan Retirement System acquired a new position in shares of Revvity in the 4th quarter valued at $3,688,000. Gulf International Bank UK Ltd bought a new stake in shares of Revvity in the 4th quarter valued at $1,136,000. Russell Investments Group Ltd. acquired a new stake in Revvity during the 4th quarter worth $10,291,000. Finally, State of Alaska Department of Revenue bought a new position in Revvity during the fourth quarter worth about $1,456,000. 86.65% of the stock is owned by institutional investors.

Revvity Stock Down 0.3 %

Shares of NYSE:RVTY traded down $0.33 during midday trading on Wednesday, reaching $102.84. The company had a trading volume of 489,319 shares, compared to its average volume of 840,835. The business's 50 day moving average price is $104.39 and its 200 day moving average price is $101.28. Revvity, Inc. has a 1-year low of $79.50 and a 1-year high of $131.96. The company has a quick ratio of 1.92, a current ratio of 2.23 and a debt-to-equity ratio of 0.40. The stock has a market cap of $12.70 billion, a PE ratio of 84.99, a P/E/G ratio of 2.62 and a beta of 1.09.

Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings results on Monday, April 29th. The company reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.04. The firm had revenue of $649.90 million for the quarter, compared to analyst estimates of $646.83 million. Revvity had a return on equity of 7.37% and a net margin of 5.49%. The business's quarterly revenue was down 3.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.01 EPS. Research analysts forecast that Revvity, Inc. will post 4.66 EPS for the current fiscal year.

Revvity Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, August 9th. Shareholders of record on Friday, July 19th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend is Friday, July 19th. Revvity's dividend payout ratio is currently 23.14%.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. KeyCorp increased their price target on Revvity from $110.00 to $126.00 and gave the stock an "overweight" rating in a report on Friday, February 2nd. Barclays raised their target price on shares of Revvity from $92.00 to $105.00 and gave the stock an "equal weight" rating in a report on Thursday, January 25th. Stifel Nicolaus increased their price objective on shares of Revvity from $95.00 to $110.00 and gave the stock a "hold" rating in a research report on Friday, February 2nd. TD Cowen raised their price objective on shares of Revvity from $123.00 to $130.00 and gave the stock a "buy" rating in a report on Tuesday, April 30th. Finally, Raymond James upped their target price on shares of Revvity from $106.00 to $127.00 and gave the stock an "outperform" rating in a research note on Friday, February 2nd. Six investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $118.17.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.